BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 17409909)

  • 1. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
    J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
    Obasaju CK; Ye Z; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Monberg MJ; Jänne PA;
    Lung Cancer; 2007 Feb; 55(2):187-94. PubMed ID: 17092602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
    Santoro A; O'Brien ME; Stahel RA; Nackaerts K; Baas P; Karthaus M; Eberhardt W; Paz-Ares L; Sundstrom S; Liu Y; Ripoche V; Blatter J; Visseren-Grul CM; Manegold C
    J Thorac Oncol; 2008 Jul; 3(7):756-63. PubMed ID: 18594322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
    Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Taylor L; Ashland J; Ye Z; Monberg MJ; Obasaju CK
    Clin Lung Cancer; 2005 Jul; 7(1):40-6. PubMed ID: 16098243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
    Vogelzang NJ; Rusthoven JJ; Symanowski J; Denham C; Kaukel E; Ruffie P; Gatzemeier U; Boyer M; Emri S; Manegold C; Niyikiza C; Paoletti P
    J Clin Oncol; 2003 Jul; 21(14):2636-44. PubMed ID: 12860938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed in malignant pleural mesothelioma.
    Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
    Taylor P; Castagneto B; Dark G; Marangolo M; Scagliotti GV; van Klaveren RJ; Labianca R; Serke M; Schuette W; van Meerbeeck JP; Heigener D; Liu Y; Adachi S; Blatter J; von Pawel J
    J Thorac Oncol; 2008 Jul; 3(7):764-71. PubMed ID: 18594323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
    Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.
    Ellis P; Davies AM; Evans WK; Haynes AE; Lloyd NS;
    J Thorac Oncol; 2006 Jul; 1(6):591-601. PubMed ID: 17409924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
    Castagneto B; Botta M; Aitini E; Spigno F; Degiovanni D; Alabiso O; Serra M; Muzio A; Carbone R; Buosi R; Galbusera V; Piccolini E; Giaretto L; Rebella L; Mencoboni M
    Ann Oncol; 2008 Feb; 19(2):370-3. PubMed ID: 18156144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
    Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
    Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nursing considerations for administering pemetrexed (Alimta) in combination with cisplatin for malignant pleural mesothelioma.
    Orbaugh KK
    Clin J Oncol Nurs; 2004 Jun; 8(3):242-7. PubMed ID: 15208818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.
    van den Bogaert DP; Pouw EM; van Wijhe G; Vernhout RM; Surmont VF; Hoogsteden HC; van Klaveren RJ
    J Thorac Oncol; 2006 Jan; 1(1):25-30. PubMed ID: 17409823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
    Hassan R; Kindler HL; Jahan T; Bazhenova L; Reck M; Thomas A; Pastan I; Parno J; O'Shannessy DJ; Fatato P; Maltzman JD; Wallin BA
    Clin Cancer Res; 2014 Dec; 20(23):5927-36. PubMed ID: 25231400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.
    Reck M; Stahel RA; von Pawel J; Karthaus M; Korfee S; Serke M; Schuette WH; Eschbach C; Fink TH; Leschinger MI; Manegold C
    Respir Med; 2010 Jan; 104(1):142-8. PubMed ID: 19818589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
    Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
    Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study.
    Kuribayashi K; Voss S; Nishiuma S; Arakawa K; Nogi Y; Mikami K; Kudoh S
    Lung Cancer; 2012 Mar; 75(3):353-9. PubMed ID: 21890228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
    Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
    J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.